- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00234052
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and pemetrexed disodium together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving carboplatin and pemetrexed disodium together with bevacizumab works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
OBJECTIVES:
Primary
- Determine the median time to disease progression in patients with stage IIIB or IV or recurrent non-squamous cell non-small cell lung cancer treated with carboplatin, pemetrexed disodium, and bevacizumab.
Secondary
- Determine the response rate and duration of response in patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
- Determine the overall survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with complete response, partial response, or stable disease continue to receive pemetrexed disodium and bevacizumab in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
Chicago, Illinois, Stati Uniti, 60612
- Rush Cancer Institute at Rush University Medical Center
-
Evanston, Illinois, Stati Uniti, 60201-1781
- Evanston Northwestern Healthcare - Evanston Hospital
-
Harvey, Illinois, Stati Uniti, 60426
- Ingalls Cancer Care Center at Ingalls Memorial Hospital
-
Park Ridge, Illinois, Stati Uniti, 60068-1174
- Advocate Lutheran General Cancer Care Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Histologically* or cytologically* confirmed non-small cell lung cancer
Any histology, except squamous cell carcinoma, allowed
- Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible
- No histology in close proximity to a major vessel or cavitation NOTE: *Histologic or cytologic elements may be established on metastatic tumor aspirates or biopsy
Meets 1 of the following stage criteria:
- Stage IIIB disease (with malignant pleural effusion)
- Stage IV disease
- Recurrent disease
- Measurable or non-measurable disease
- No known CNS metastases by CT scan or MRI
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count > 1,500/mm^3
- Platelet count > 100,000/mm^3
- No history of hemorrhagic disorders
Hepatic
- Bilirubin < 1.5 mg/dL
- AST and ALT < 5 times upper limit of normal
- INR < 1.5
- PTT normal
Renal
- Creatinine clearance ≥ 45 mL/min
- Urine protein:creatinine ≤ 1.0 by spot urinalysis
Cardiovascular
- No myocardial infarction within the past 6 months
- No New York Heart Association class II-IV congestive heart failure
- No unstable angina pectoris
- No serious cardiac arrhythmia requiring medication
- No stroke within the past 6 months
- No peripheral vascular disease ≥ grade 2
No uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg)
- Patients with a history of hypertension allowed provided blood pressure is well controlled on a stable regimen of anti-hypertensive therapy
- No history of thrombotic disorders
- No other clinically significant cardiovascular disease
Pulmonary
- No history of gross hemoptysis, defined as bright red blood of a ½ teaspoon or more
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Must be willing and able to take daily oral folic acid, intermittent vitamin B_12 injections, and corticosteroid premedication
- No ongoing or active infection
- No serious, non-healing wound, ulcer, or bone fracture
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
- No psychiatric illness or social situation that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 3 weeks since prior immunotherapy
Chemotherapy
- No prior systemic chemotherapy
Endocrine therapy
- More than 3 weeks since prior hormonal therapy
Radiotherapy
- See Disease Characteristics
- More than 3 weeks since prior radiotherapy
Surgery
- More than 4 weeks since prior major surgery
- More than 1 week since prior minor surgery, fine needle aspiration, or core biopsy
- No concurrent major surgery
Other
- Recovered from all prior therapy
- More than 4 weeks since prior and no concurrent participation in another experimental drug study
- No aspirin or other nonsteroidal anti-inflammatory drug (NSAID) 2 days before and 2 days after each pemetrexed disodium infusion (5 days before and 2 days after each pemetrexed disodium infusion for NSAIDs with a long half-life [e.g., naproxen, rofecoxib, or celecoxib])
No concurrent therapeutic anticoagulation
- Concurrent prophylactic anticoagulation for venous access devices allowed provided requirements for INR and PTT are met
No concurrent administration of any of the following:
- Chronic daily treatment with aspirin (> 325 mg per day)
NSAIDs known to inhibit platelet function, including any of the following:
- Dipyridamole
- Ticlopidine
- Clopidogrel
- Cilostazol
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Treatment Arm
Carboplatin + pemetrexed + bevacizumab
|
5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
Altri nomi:
Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Median Progression Free Survival
Lasso di tempo: Approximately every 3 weeks until disease progression or death. Median follow up of 13 months (range 0.8 to 34.4 months)
|
Progression Free Survival (PFS) in patients treated with the combination of carboplatin, pemetrexed and bevacizumab is defined as the time from registration to the time of documented disease progression or death from any cause.
Patients that were lost to follow up or withdrew consent were censored at that point.
|
Approximately every 3 weeks until disease progression or death. Median follow up of 13 months (range 0.8 to 34.4 months)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Overall Response Rate
Lasso di tempo: Every two cycles until disease progression. Median follow up of 13 months (range 0.8 to 34.4 months)
|
Overall Response Rate (ORR) of patients treated with carboplatin, pemetrexed, and bevacizumab combination is defined as the number of patients who's best response is a Complete Response (CR) plus Partial Response (PR)as recorded from the start of treatment until disease progression as assessed by RECIST 1.0. CR=Disappearance of all target lesions for a minimum of 4 weeks. PR=At least a 30% decrease in the sum of the longest diameter (LD) of target lesions for a minimum of 4 weeks, taking as reference the baseline sum LD. No simultaneous increase in the size of any lesion or the appearance of a new lesion may occur. |
Every two cycles until disease progression. Median follow up of 13 months (range 0.8 to 34.4 months)
|
Toxicity of Carboplatin, Pemetrexed and Bevacizumab Combination Treatment
Lasso di tempo: From treatment initiation, at the beginning of each cycle where one cycle equals 21 days until 30 days post treatment (range of cycles 1-51)
|
To characterize the toxicity profile of carboplatin, pemetrexed and bevacizumab combination treatment. Toxicity data will be collected from initiation of treatment, every cycle, until 30 days post last treatment. Adverse events will be graded according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). Only toxicity determined to be a least possibility related to at least one study drug and grade 3 or 4 was collected for this outcome measure. In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
From treatment initiation, at the beginning of each cycle where one cycle equals 21 days until 30 days post treatment (range of cycles 1-51)
|
Overall Survival Rate
Lasso di tempo: During treatment and then every 3 months x 2 years, then every 6 months x 3 years or until death.
|
Overall Survival (OS) Rate of carboplatin, pemetrexed and bevacizumab combination treatment is defined from the time of registration to the study until death from any cause.
Patients that are lost to follow up will be censored from last documentation of survival status.
|
During treatment and then every 3 months x 2 years, then every 6 months x 3 years or until death.
|
Duration of Response
Lasso di tempo: From documentation of response, every two cycles (1 cycle = 21 days) until progressive disease with range of cycles completed 1-51.
|
Duration of Response for patients treated with the combination of carboplatin, pemetrexed and bevacizumab is measured from the time measurement criteria are met for Complete Response or Partial Response (whichever is first recorded) until the first date of documented progressive disease.
|
From documentation of response, every two cycles (1 cycle = 21 days) until progressive disease with range of cycles completed 1-51.
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Jyoti D. Patel, Robert H. Lurie Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie polmonari
- Carcinoma, polmone non a piccole cellule
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori della sintesi degli acidi nucleici
- Inibitori enzimatici
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Antagonisti dell'acido folico
- Carboplatino
- Bevacizumab
- Pemetrexed
Altri numeri di identificazione dello studio
- NU 04L2
- NU-04L2
- STU00007415 (Altro identificatore: Northwestern University IRB#)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro ai polmoni
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su bevacizumab
-
National Cancer Institute (NCI)Attivo, non reclutanteCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Cistodenocarcinoma ovarico a cellule chiare | Adenocarcinoma endometrioide ovarico | Cistodenocarcinoma sieroso ovarico | Adenocarcinoma endometriale a cellule chiare | Adenocarcinoma... e altre condizioniStati Uniti
-
M.D. Anderson Cancer CenterReclutamentoCarcinoma epatocellulare in stadio IB AJCC v8 | Carcinoma epatocellulare in stadio II AJCC v8 | Carcinoma epatocellulare resecabile | Carcinoma epatocellulare stadio I AJCC v8 | Stadio IA Carcinoma epatocellulare AJCC v8Stati Uniti
-
National Cancer Institute (NCI)CompletatoAdenocarcinoma cervicale | Carcinoma adenosquamoso cervicale | Carcinoma a cellule squamose della cervice, non altrimenti specificato | Stadio IVA Cancro cervicale AJCC v6 e v7 | Carcinoma cervicale ricorrente | Cancro cervicale in stadio IV AJCC v6 e v7 | Stadio IVB Cancro cervicale AJCC v6 e v7Stati Uniti
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ReclutamentoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Adenocarcinoma endometrioide ovarico | Adenocarcinoma ovarico a cellule chiare | Adenocarcinoma della tuba di Falloppio | Adenocarcinoma sieroso delle tube di Falloppio | Adenocarcinoma... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteMelanoma cutaneo di stadio IV AJCC v6 e v7 | Melanoma cutaneo in stadio IIIC AJCC v7 | Melanoma non resecabileStati Uniti
-
National Cancer Institute (NCI)NRG OncologyCompletatoGlioblastoma | Gliosarcoma | Glioblastoma ricorrente | Oligodendrogliomi | Glioblastoma a cellule giganti | Neoplasia cerebrale ricorrenteStati Uniti, Canada
-
National Cancer Institute (NCI)ReclutamentoSarcoma metastatico della parte molle alveolare | Sarcoma della parte molle alveolare non resecabileStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteAdenocarcinoma endometrioide ovarico | Adenocarcinoma sieroso peritoneale primario di alto grado | Adenocarcinoma endometrioide delle tube di Falloppio | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Adenocarcinoma sieroso ovarico... e altre condizioniStati Uniti, Canada
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletatoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Carcinoma ovarico resistente al platino | Carcinoma ovarico... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteGlioblastoma ricorrenteStati Uniti